UNITED STATES INTERNATIONAL TRADE COMMISSION Washington, D.C.

In the Matter of

CERTAIN NON-INVASIVE AESTHETIC BODY-CONTOURING DEVICES, COMPONENTS THEREOF, AND METHODS OF USING THE SAME **Investigation No. 337-TA-1219**

NOTICE OF A COMMISSION DETERMINATION NOT TO REVIEW AN INITIAL DETERMINATION GRANTING AN UNOPPOSED MOTION TO TERMINATE THE INVESTIGATION AS TO CERTAIN ASSERTED PATENT CLAIMS

AGENCY: U.S. International Trade Commission.

ACTION: Notice.

SUMMARY: Notice is hereby given that the U.S. International Trade Commission ("Commission") has determined not to review an initial determination ("ID") (Order No. 15) of the presiding administrative law judge ("ALJ") granting an unopposed motion to terminate the investigation as to certain patent claims.

FOR FURTHER INFORMATION CONTACT: Panyin A. Hughes, Office of the General Counsel, U.S. International Trade Commission, 500 E Street, S.W., Washington, D.C. 20436, telephone (202) 205-3042. Copies of non-confidential documents filed in connection with this investigation may be viewed on the Commission's electronic docket (EDIS) at https://edis.usitc.gov. For help accessing EDIS, please email EDIS3Help@usitc.gov. General information concerning the Commission may also be obtained by accessing its Internet server at https://www.usitc.gov. Hearing-impaired persons are advised that information on this matter can be obtained by contacting the Commission's TDD terminal, telephone (202) 205-1810.

SUPPLEMENTARY INFORMATION: On September 9, 2020, the Commission instituted this investigation based on a complaint filed by BTL Industries, Inc. ("BTL") of Marlborough, Massachusetts. 85 FR 55687-88 (Sept. 9, 2020). The complaint alleged violations of section 337 based on the importation into the United States, the sale for importation, or the sale within the United States after importation of certain non-invasive aesthetic body-contouring devices, components thereof, and methods of using the same by reason of infringement of claims 1, 2, 4, 6-8, 10, 12-16, 20, 22, 23, and 26-28 of U.S. Patent No.10,632,321 ("the '321 patent"); claims 1, 9-11, 13, 15, 16, and 20-22 of U.S. Patent No. 10,695,575 ("the '575 patent"); claims 1, 8, 10, 11, 13, 16, 18, 23-25, 27, and 28 of ("the '576 patent"); claims 1, 2, 4, 5, 9, 10, 12, 13, 17-21, 23, 24, and 26-29 of ("the '894 patent"); claims 1, 2-6, 9, 10, and 14-25 of U.S. Patent No. 10,709,895 ("the '895 patent"); and claims 1, 6, 7, 16, 21, and 22 of U.S. Patent No. 10,478,634 ("the '634 patent"). *Id.* at 55687. The Commission's notice of investigation named the following

six respondents: Allergan Limited of Dublin, Ireland; Allergan USA, Inc. of Madison, New Jersey; Allergan, Inc. of Madison, New Jersey; Zeltiq Aesthetics, Inc. of Pleasanton, California; Zeltiq Ireland Unlimited Company of Galway, Ireland; and Zimmer MedizinSysteme GmbH of Neu-Ulm, Germany (collectively, "Respondents"). The Office of Unfair Import Investigations was not named as a party in this investigation. *Id*.

On March 12, 2021, BTL moved to terminate the investigation as to (1) claims 1, 2, 4, 6, 7, 15, 16, 20, 22, 23, and 26–28 of the '321 patent; (2) claims 1, 20, and 21 of the '575 patent; (3) claims 1, 24, and 25 of the '576 patent; (4) claims 1, 2, 4, 5, 19, 20, 21, 23, 24, 26, and 29 of the '894 patent; (5) claims 9, 10, 15, 16, 18, 24, 25 of the '895 patent; and (6) claims 1, 6, 7, and 21 of the '634 patent. On March 18, 2021, Respondents filed a response in support of the motion.

On April 1, 2021, the ALJ issued the subject ID (Order No. 15) granting BTL's unopposed motion. The subject ID finds that the motion complies with Commission Rule 210.21(a)(1), which provides that "[a]ny party may move at any time prior to the issuance of an initial determination on violation of section 337 of the Tariff Act of 1930 to terminate an investigation in whole or in part ... on the basis of withdrawal of the complaint or certain allegations contained therein...." 19 CFR 210.21(a)(1). ID at 2. The ID further finds that in compliance with 19 CFR 210.21(a)(1), "BTL confirms that there are no agreements, written or oral, express or implied, between the parties concerning the subject matter of the investigation" and that there are no extraordinary circumstances that warrant denying the motion. *Id.* at 3-4.

The Commission has determined not to review the subject ID. The investigation is hereby terminated as to (1) claims 1, 2, 4, 6, 7, 15, 16, 20, 22, 23, and 26–28 of the '321 patent; (2) claims 1, 20, and 21 of the '575 patent; (3) claims 1, 24, and 25 of the '576 patent; (4) claims 1, 2, 4, 5, 19, 20, 21, 23, 24, 26, and 29 of the '894 patent; (5) claims 9, 10, 15, 16, 18, 24, 25 of the '895 patent; and (6) claims 1, 6, 7, and 21 of the '634 patent.

The Commission vote for this determination took place on April 27, 2021.

The authority for the Commission's determination is contained in section 337 of the Tariff Act of 1930, as amended (19 U.S.C. 1337), and in Part 210 of the Commission's Rules of Practice and Procedure (19 CFR Part 210).

By order of the Commission.

Lisa R. Barton

Secretary to the Commission

Issued: April 27, 2021